Valuation
- Market cap
- 947,435,000
- Revenue TTM
- $67,480,000
- Net income TTM
- $-278,670,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- -412.97%
- Debt to equity
- 0.20
Trading
- Volume
- 1,887,300
- Avg volume
- 1,940,904
- Day's range
- $10.59 – $10.97
- Shares out
- 88,961,000
- Stochastic %K
- 18%
- Beta
- 0.47
- Analysts
- Strong Sell
- Price target
- $31.85
Company profile
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tum...
Show more
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 858 500 8800
- Website
- https://kuraoncology.com
- Address
- 4930 Directors Place, Suite 500, San Diego, United States
Latest news
No headlines yet.
